Skip to main content

Home/ Nutrition/ Group items tagged high-dose

Rss Feed Group items tagged

Matti Narkia

Twice single doses of 100,000 IU of vitamin D in winter is adequate and safe ... - 1 views

  •  
    Twice single doses of 100,000 IU of vitamin D in winter is adequate and safe for prevention of vitamin D deficiency in healthy children from Ushuaia, Tierra Del Fuego, Argentina.
    Tau C, Ciriani V, Scaiola E, Acuña M.
    J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):651-4. Epub 2007 Jan 25.
    PMID: 17257830
    doi:10.1016/j.jsbmb.2006.12.027

    These results disclosed that to prevent vitamin D deficiency for children at zones of risk at the south of our country, double supplementation of 100,000 IU of vitamin D during autumn and winter, would be adequate and safe.
Matti Narkia

High-dose vitamin D3 supplementation in a cohort of breastfeeding mothers and their inf... - 0 views

  •  
    High-dose vitamin D3 supplementation in a cohort of breastfeeding mothers and their infants: a 6-month follow-up pilot study.
    Wagner CL, Hulsey TC, Fanning D, Ebeling M, Hollis BW.
    Breastfeed Med. 2006 Summer;1(2):59-70.
    PMID: 17661565
    doi:10.1089/bfm.2006.1.59.

    Objective: To examine the effect of high-dose maternal vitamin D3 (vitD) supplementation on the nutritional vitD status of breastfeeding (BF) women and their infants compared with maternal and infant controls receiving 400 and 300 IU vitD/day, respectively.

    Design: Fully lactating women (n = 19) were enrolled at 1-month postpartum into a randomized- control pilot trial. Each mother received one of two treatments for a 6-month study period: 0 or 6000 IU vitD3 plus a prenatal vitamin containing 400 IU vitD3. The infants of mothers assigned to the control group received 300 IU vitD3/day; those infants of mothers in the high-dose group received 0 IU (placebo). Maternal serum and milk vitD and 25(OH)D were measured at baseline then monthly; infant serum vitD and 25(OH)D were measured at baseline, and months 4 and 7. Urinary calcium/creatinine ratios were measured monthly in both mothers and infants. Dietary and BF history and outdoor activity questionnaires were completed at each visit. Changes in skin pigmentation were measured by spectrophotometry. Data were analyzed using chi-square, t-test, and analysis of variance (ANOVA) on an intent-to-treat basis.

    Conclusion: With limited sun exposure, an intake of 400 IU/day vitamin D3 did not sustain circulating maternal 25(OH)D levels, and thus, supplied only extremely limited amounts of vitamin D to the nursing infant via breast milk. Infant levels achieved exclusively through maternal supplementation were equivalent to levels in infants who received oral vitamin D supplementation. Thus, a maternal intake of 6400 IU/day vitamin D elevated circulating 25(OH)D in both mother and nursing infant.
Matti Narkia

A phase 2 trial exploring the effects of high-dose (10,000 IU/day) vitamin D(3) in brea... - 0 views

  •  
    A phase 2 trial exploring the effects of high-dose (10,000 IU/day) vitamin D(3) in breast cancer patients with bone metastases.
    Amir E, Simmons CE, Freedman OC, Dranitsaris G, Cole DE, Vieth R, Ooi WS, Clemons M.
    Cancer. 2009 Nov 13. [Epub ahead of print]
    PMID: 19918922
    DOI: 10.1002/cncr.24749

    METHODS:
    Patients with bone metastases treated with bisphosphonates were enrolled into this single-arm phase 2 study. Patients received 10,000 IU of vitamin D3 and 1000 mg of calcium supplementation each day for 4 months. The effect of this treatment on palliation, bone resorption markers, calcium metabolism, and toxicity were evaluated at baseline and monthly thereafter.


    CONCLUSIONS:
    Daily doses of 10,000 IU vitamin D3 for 4 months appear safe in patients without comorbid conditions causing hypersensitivity to vitamin D. Treatment reduced inappropriately elevated parathyroid hormone levels, presumably caused by long-term bisphosphonate use. There did not appear to be a significant palliative benefit nor any significant change in bone resorption. Cancer 2010. © 2009 American Cancer Society.
Matti Narkia

High-dose fish oil for Lp(a) - The Heart Scan Blog - 1 views

  •  
    "Lipoprotein(a), or Lp(a), is a problem area in coronary plaque reversal.

    While our current Track Your Plaque record holder for largest percentage reduction in heart scan score has Lp(a), it remains among the more troublesome lipoprotein patterns.

    One unique treatment for Lp(a) is high-dose omega-3 fatty acids from fish oil. While the data are relatively meager, there is one solid study from Lp(a) expert, Dr. Santica Marcovina of the University of Washington, called "The Lugalawa Study."

    In this unique set of observations, 1300 members of a Bantu tribe living in Tanzania were studied. What made this population unusual is the fact that two groups of Bantus lived under different circumstances. One group lived on Nyasa Lake (3rd largest lake in Africa and reputed to have the greatest number of species of fish of any lake in the world) and ate large quantities of freshwater fish providing up to 500 mg of omega-3s, EPA and DHA, per day. Another Bantu group lived away from the lake as farmers, eating a pure vegetarian diet without fish. "
Matti Narkia

High doses of vitamin D could cut relapse rate among MS sufferers - Times Online - 0 views

  •  
    "Powerful new evidence about the ability of vitamin D to stem a wide range of diseases has brought the prospect of a nationwide programme to prescribe it in Scotland as a dietary supplement significantly closer.

    Reports at the weekend suggested that experts were increasingly convinced that the so-called sunshine drug - whose significance was first revealed in detail by The Times last year - could make a difference to the country's appalling health record.

    New research suggests that high doses of vitamin D could dramatically cut the relapse rate in people with multiple sclerosis. According to scientists in Canada, more than a third of sufferers taking high levels of supplement
Matti Narkia

Safety of vitamin D3 in adults with multiple sclerosis -- Kimball et al. 86 (3): 645 --... - 0 views

  •  
    Safety of vitamin D3 in adults with multiple sclerosis.
    Kimball SM, Ursell MR, O'Connor P, Vieth R.
    Am J Clin Nutr. 2007 Sep;86(3):645-51.
    PMID: 17823429

    Conclusions: Patients' serum 25(OH)D concentrations reached twice the top of the physiologic range without eliciting hypercalcemia or hypercalciuria. The data support the feasibility of pharmacologic doses of vitamin D3 for clinical research, and they provide objective evidence that vitamin D intake beyond the current upper limit is safe by a large margin.
Matti Narkia

Vitamin D and MS: Burton - 0 views

  •  
    "Dr. Jodie Burton is the acting principal investigator (PI) of the dose-escalation trial of oral vitamin D3 with calcium supplementation in patients with multiple sclerosis with Dr. O'Connor. She started the trial as his fellow, while doing an additional 2 years of training in MS specifically after she received her neurology certification. She completed her fellowship training in 2007. Now she is staff doing clinical research and continuing with the vitamin D trial. As of August 2009, she will be Assistant Professor in Neurology in the Department of Clinical Neuroscience in Calgary and at the University of Calgary. She will be part of the MS team there with Dr. Luanne Metz and the MS group.

    Please scroll down for an abstract of the trial:
    A Phase I/II dose-escalation trial of oral vitamin D3 with calcium supplementation in patients with multiple sclerosis."

    Conclusions:
    High-dose VD3 (~10 000 IU/day, possibly higher) in MS is safe and tolerable, with evidence of clinical improvement."
Matti Narkia

High Doses of Vitamin D Cut MS Relapses - 0 views

  •  
    "April 28, 2009 (Seattle) -- High doses of vitamin D dramatically cut the relapse rate in people with multiple sclerosis, a study shows.

    Sixteen percent of 25 people with multiple sclerosis (MS) given an average of 14,000 international units (IU) of vitamin D a day for a year suffered relapses, says Jodie Burton, MD, a neurologist at the University of Toronto. In contrast, close to 40% of 24 MS patients who took an average of 1,000 IU a day -- the amount recommended by many MS specialists -- relapsed, she says.

    Also, people taking high-dose vitamin D suffered 41% fewer relapses than the year before the study began, compared with 17% of those taking typical doses.

    People taking high doses of vitamin D did not suffer any significant side effects, Burton tells WebMD."
Matti Narkia

Vitamin D requirements during lactation: high-dose maternal supplementation as therapy ... - 0 views

  •  
    Vitamin D requirements during lactation: high-dose maternal supplementation as therapy to prevent hypovitaminosis D for both the mother and the nursing infant.
    Hollis BW, Wagner CL.
    Am J Clin Nutr. 2004 Dec;80(6 Suppl):1752S-8S.
    PMID: 15585800
Matti Narkia

Pharmacokinetics of a single, large dose of cholecalciferol -- Ilahi et al. 87 (3): 688... - 0 views

  •  
    Pharmacokinetics of a single, large dose of cholecalciferol.
    Ilahi M, Armas LA, Heaney RP.
    Am J Clin Nutr. 2008 Mar;87(3):688-91.
    PMID: 1832660

    Conclusions: Cholecalciferol (100 000 IU) is a safe, effective, and simple way to increase calcidiol concentrations. The dosing interval should be ≤2 mo to ensure continuous serum calcidiol concentrations above baseline.

    Our study highlights that 100 000 IU cholecalciferol is a safe, efficient, and cost-effective means to increase calcidiol concentrations in the elderly. From this study we can safely recommend 100 000 IU cholecalciferol dosed every 2 mo in persons with moderate baseline calcidiol concentrations. However, in those persons with baseline calcidiol concentrations < 20 ng/mL, even this large dose will not adequately raise their calcidiol concentrations.
Matti Narkia

eMJA: Annual intramuscular injection of a megadose of cholecalciferol for treatment of ... - 0 views

  •  
    Annual intramuscular injection of a megadose of cholecalciferol for treatment of vitamin D deficiency: efficacy and safety data. Diamond TH, Ho KW, Rohl PG, Meerkin M.
    Med J Aust. 2005 Jul 4;183(1):10-2.
    PMID: 15992330

    Conclusions: Once-yearly intramuscular cholecalciferol injection (600 000 IU) is effective therapy for vitamin D deficiency. While this therapy appears to be safe, the potential for developing hypercalciuria needs to be examined in a large randomised controlled trial.
Matti Narkia

High-dose oral vitamin D3 supplementation in the elderly. - [Osteoporos Int. 2009] - Pu... - 0 views

  •  
    High-dose oral vitamin D3 supplementation in the elderly.
    Bacon CJ, Gamble GD, Horne AM, Scott MA, Reid IR.
    Osteoporos Int. 2009 Aug;20(8):1407-15. Epub 2008 Dec 20.
    PMID: 19101755

    Sixty-three elderly participants were randomized to three regimens of vitamin D supplementation: a 500,000-IU loading dose; the loading dose plus 50,000 IU/month; or 50,000 IU/month.

    CONCLUSIONS: Large loading doses of vitamin D(3) rapidly and safely normalize 25OHD levels in the frail elderly. Monthly dosing is similarly effective and safe, but takes 3-5 months for plateau 25OHD levels to be reached.
Matti Narkia

Nutritional intervention with omega-3 Fatty acids in a case of malignant fibrous histio... - 0 views

  •  
    Nutritional intervention with omega-3 Fatty acids in a case of\nmalignant fibrous histiocytoma of the lungs.
    Pardini RS, Wilson D, Schiff S, Bajo SA, Pierce R.
    Nutr Cancer. 2005;52(2):121-9.
    PMID: 16201843
Matti Narkia

The effect of dietary omega-3 polyunsaturated fatty acids on T-lymphocyte subsets of pa... - 0 views

  •  
    The effect of dietary omega-3 polyunsaturated fatty acids on T-lymphocyte subsets of patients with solid tumors.
    Gogos CA, Ginopoulos P, Zoumbos NC, Apostolidou E, Kalfarentzos F.
    Cancer Detect Prev. 1995;19(5):415-7.
    PMID: 7585727
Matti Narkia

Omega-3 fatty acid supplementation decreases matrix metalloproteinase-9 production in r... - 0 views

  •  
    Omega-3 fatty acid supplementation decreases matrix metalloproteinase-9 production in relapsing-remitting multiple sclerosis(,).
    Shinto L, Marracci G, Baldauf-Wagner S, Strehlow A, Yadav V, Stuber L, Bourdette D.
    Prostaglandins Leukot Essent Fatty Acids. 2009 Feb-Mar;80(2-3):131-6. Epub 2009 Jan 25.
    PMID: 19171471
    doi:10.1016/j.plefa.2008.12.001
Matti Narkia

Nutritional intervention with omega-3 Fatty acids in a case of malignant fibrous histio... - 0 views

  •  
    Nutritional intervention with omega-3 Fatty acids in a case of
    malignant fibrous histiocytoma of the lungs.
    Pardini RS, Wilson D, Schiff S, Bajo SA, Pierce R.
    Nutr Cancer. 2005;52(2):121-9.
    PMID: 16201843
Matti Narkia

Long-term effects of giving nursing home residents bread fortified with 125 microg (500... - 0 views

  •  
    Long-term effects of giving nursing home residents bread fortified with 125 microg (5000 IU) vitamin D(3) per daily serving.
    Mocanu V, Stitt PA, Costan AR, Voroniuc O, Zbranca E, Luca V, Vieth R.
    Am J Clin Nutr. 2009 Apr;89(4):1132-7. Epub 2009 Feb 25.
    PMID: 19244376
    doi:10.3945/ajcn.2008.26890
Matti Narkia

Clinical aspects of vitamin D in the management of rheumatoid arthritis. - Rheumatology... - 0 views

  •  
    Clinical aspects of vitamin D in the management of rheumatoid arthritis.\nLeventis P, Patel S.\nRheumatology (Oxford). 2008 Nov;47(11):1617-21. Epub 2008 Aug 5. Review.\nPMID: 18682414 \ndoi:10.1093/rheumatology/ken296 \n
Matti Narkia

The controversial place of vitamin C in cancer treatment - ScienceDirect - Biochemical ... - 0 views

  •  
    The controversial place of vitamin C in cancer treatment.
    Verrax J, Calderon PB.
    Biochem Pharmacol. 2008 Dec 15;76(12):1644-52. Epub 2008 Sep 30. Review.
    PMID: 18938145
    doi:10.1016/j.bcp.2008.09.024    
Matti Narkia

A pilot clinical study of continuous intravenous a...[P R Health Sci J. 2005] - PubMed ... - 0 views

  •  
    A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients.
    Riordan HD, Casciari JJ, González MJ, Riordan NH, Miranda-Massari JR, Taylor P, Jackson JA.
    P R Health Sci J. 2005 Dec;24(4):269-76.
    PMID: 16570523
1 - 20 of 29 Next ›
Showing 20 items per page